Romiplostim

Romiplostim (Nplate) is a real, FDA-approved "peptibody" — an antibody-Fc fragment fused to peptide domains that mimic thrombopoietin — for chronic immune thrombocytopenia, carrying a boxed warning about a risk this site's other GH-secretagogue-adjacent peptides don't face: progression to leukemia in a specific patient population it isn't approved for.

What a "peptibody" is

Romiplostim is structurally different from most entries on this site: it's the Fc domain of human IgG1 (the same long-half-life antibody fragment used in many biologic drugs) genetically fused to peptide sequences that bind and activate the thrombopoietin (TPO) receptor on megakaryocytes, stimulating platelet production. Those peptide domains have no amino acid sequence resemblance to natural thrombopoietin at all — they were engineered from scratch to bind the same receptor. This Fc-peptide fusion format ("peptibody") is why romiplostim can be dosed weekly rather than needing the much more frequent dosing a plain small peptide would require.

The approval and pivotal trial

The FDA approved romiplostim (as Nplate) on 22 August 2008 for adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who hadn't responded adequately to corticosteroids, immunoglobulins, or splenectomy. The pivotal trial (Kuter et al., Lancet 2008, PMID 18242413) ran two parallel studies in splenectomized and non-splenectomized ITP patients, finding romiplostim increased and maintained platelet counts in both groups, with many patients able to reduce or stop other ITP medications. The drug has since been approved for pediatric ITP and, more recently, for aplastic anemia — we could not confirm the exact dates of those label expansions and would treat them as needing direct verification against FDA's own announcement pages.

The boxed warning

Nplate carries an FDA boxed warning: in a dedicated trial of patients with myelodysplastic syndrome (MDS) — a different blood disorder romiplostim is not approved to treat — the study was stopped early after more cases of progression to acute myeloid leukemia (AML) appeared in the romiplostim arm. Nplate's label explicitly states it is not indicated for thrombocytopenia due to MDS or any cause other than ITP. Separately, about 7% of ITP trial patients (9 of 131) showed an increase in bone marrow reticulin fiber deposition, which generally improved after stopping the drug and hasn't been definitively linked to clinical harm, though the FDA still flags it. A longer-term 5-year MDS follow-up study reportedly found no statistically significant difference in AML transformation between romiplostim and placebo arms — a real finding that somewhat softens, but doesn't eliminate, the original signal.

Current status

Still marketed by Amgen, with reported quarterly sales in the hundreds of millions of dollars. This is a specialty hematology drug with no wellness, cosmetic, or grey-market presence.